Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q3 FY26
Glenmark delivered a strong Q3 with consolidated revenue of ₹3,962 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark delivered a strong Q3 with consolidated revenue of ₹3,962 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds. India formulation grew 22.1% YoY, outperforming the IPM, while the US business (ex-outlicensing) rose 4.1%. EBITDA margin came in at 23%, in line with guidance. Management highlighted the Monroe facility's VAI status as a key strategic win, enabling future respiratory and injectable launches. The innovative pipeline, including Ryaltris (now ~$100M run-rate) and upcoming launches of Omalotinib and Trastutumab, underpins a multi-year growth trajectory. Risks include delayed USFDA approvals for Flovent generics and working capital normalization challenges.
ग्लेनमार्क ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई ₹3,962 करोड़ रही, जो पिछले साल से 15.1% ज़्यादा है। यह बढ़ोतरी भारत और दूसरे बाज़ारों में बिक्री बढ़ने और विदेशी मुद्रा के फ़ायदे से हुई। भारत में दवाओं की बिक्री 22.1% बढ़ी, जो पूरे बाज़ार से बेहतर है। अमेरिका में बिक्री (लाइसेंस छोड़कर) 4.1% बढ़ी। कंपनी का मुनाफ़ा मार्जिन 23% रहा, जो अनुमान के मुताबिक है। मुनरो फैक्ट्री को मंज़ूरी मिलना बड़ी जीत है, जिससे नई साँस और इंजेक्शन वाली दवाएँ लॉन्च होंगी। नई दवाओं जैसे रायल्ट्रिस (अब ~$100 करोड़ की बिक्री) और ओमालोटिनिब से आने वाले सालों में कमाई बढ़ेगी। जोखिमों में अमेरिकी मंज़ूरी में देरी और कार्यशील पूंजी का सही न होना शामिल है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
USFDA approval delays for respiratory products
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India Formulation Sales Growth
22.1%
+22.1% YoY
India formulation sales grew 22.1% YoY to ₹1,299 crore, significantly outperforming the IPM growth of 10.9%.
Ryaltris Global Sales Run-rate
$100M
+50%+ YoY
Ryaltris global secondary sales grew over 50% YoY, now at a $100 million annual run-rate, with launches in 52 markets.
Net Working Capital Days
110 days
-15 days YoY
Net working capital days improved to ~110 days, ahead of the 115-day target for March 2026, driven by factoring and vendor financing.
R&D Spend
₹290 Cr
N/A
Total R&D spend for Q3 was ₹290 crore, with ~50% allocated to IGI (innovative pipeline), consistent with the guided $70M annual burn rate.
What Changed vs Last Quarter
NEW
EBITDA margin guidance of 23% sustainable
Management reiterated that the 23% EBITDA margin is sustainable and expects improvement from FY28 onwards as innovative assets scale.
NEW
Net working capital days at 115 by March 2026
Working capital days are expected to normalize to 115 days by year-end, with current levels already at ~110 days.
NEW
Flovent 44 mcg ANDA approval expected in Q4
Management expects USFDA approval for generic Flovent 44 mcg in Q4 FY26, which could drive US growth.
UPDATED
Gross debt zero by March 2026
The company targets gross debt to be zero by March 2026, supported by net cash positive position of ~₹600 crore.
DROPPED
India business run-rate of ₹1,150-1,200 crore from Q3 FY26
Management expects India formulation sales to normalize to ₹1,150-1,200 crore per quarter starting Q3 FY26, with FY27 revenue exceeding ₹4,800 crore.
DROPPED
FY27 consolidated revenue target of ₹17,000-18,000 crore
Management guided FY27 topline between ₹17,000-18,000 crore, implying ~15% growth over FY26 estimated run-rate.
DROPPED
EBITDA margin of 23% immediately, targeting 25%+
Post balance sheet cleanup, EBITDA margin will trend to 23% and strengthen to over 25% in coming years.
NEW RISK
USFDA approval delays for respiratory products
Approval for Flovent 44 mcg and other respiratory ANDAs may be delayed, impacting Q4 US revenue expectations.
NEW RISK
Currency depreciation impact on reported growth
While currency tailwinds boosted reported revenue, constant currency growth in Europe may be lower than reported 9.1%.
NEW RISK
Gross margin pressure from product mix
Excluding outlicensing income, gross margin was ~65%, impacted by product and geographic mix; recovery depends on new product approvals.
NEW RISK
Working capital normalization challenges
Despite progress, working capital days may face pressure from business growth and payment cycles in emerging markets.
RISK GONE
India distribution disruption from GST change
The three-tier distribution model caused a one-time 87% drop in primary sales due to inventory destocking; similar regulatory changes could recur.
RISK GONE
Recurring write-offs and litigation costs
Analyst highlighted past write-offs (Mondro, Zeta, antitrust) totaling significant amounts; management acknowledged but offered limited assurance on future controls.
RISK GONE
IGI pipeline execution risk
ISB 2301 and three other multi-specific programs are preclinical; failure to advance or partner could impair value.
RISK GONE
Geopolitical uncertainty in emerging markets
EM revenue declined 6.5% due to geopolitical issues in Latin America and West Africa; recovery uncertain.
Fast read
Guidance and risk preview
Management reiterated that the 23% EBITDA margin is sustainable and expects improvement from FY28 onwards as innovative assets scale.
Approval for Flovent 44 mcg and other respiratory ANDAs may be delayed, impacting Q4 US revenue expectations.
View Risks →